pERK-expressing HCC tissues show a marked increase in CD8 + CTLs in the tumor and a high PD-1 expression, suggesting that anti-PD-1 therapy could overcome sorafenib resistance in HCC [190]. This evidence concerns the gene CD8A and hepatocellular carcinoma.